La dernière actualité médicale HaemophiliaXPERT
Consultez la version en ligne
|
|
|
Chère consœur, cher confrère,
|
| Retrouvez ci-après les dernières publications scientifiques issues de revues à comité de lecture dans votre domaine d'expertise. |
|
| Publications du 25 janvier 2026 |
| Competence and Confidence: An Evaluation of Physiotherapists' Knowledge and Self-Perception About Physical Activity and Exercise in Patients With Haemophilia. |
| Haemophilia : the official journal of the World Federation of Hemophilia 2025 Nov |
Physiotherapists are irreplaceable in providing safe, tailored physical activity (PA) and exercise in patients with haemophilia (PwH).Aim: Evaluating physiotherapists' knowledge, self-perceived competence,...
En savoir plus
|
Free Full-text
|
| Real-World Experience with Eptacog Beta for On-Label and Off-Label Indications: The Spanish Experience. |
| Pharmaceuticals (Basel, Switzerland) 2025 Oct; 18(11) |
Eptacog beta is a novel recombinant activated factor VII (rFVIIa). Preclinical studies have shown the product has a similar profile to eptacog alfa. The PERSEPT 1 and PERSEPT 3 trials proved the efficacy...
En savoir plus
|
Free Full-text
|
| Eight-Week Resistance Training and Manual Therapy in Young Patients with Severe Hemophilia: A Case Series Evaluating Functional, Imaging, and Immunological Outcomes. |
| Journal of clinical medicine 2025 Nov; 14(23) |
Hemophilia A and B are hereditary bleeding disorders that result in recurrent joint and muscle hemorrhages, leading to hemophilic arthropathy, muscle atrophy, and disability. Recent evidence suggests that...
En savoir plus
|
Free Full-text
|
| Recurrence of FVIII Inhibitor during Surgery in a Patient with Severe Hemophilia A Receiving Emicizumab Prophylaxis. |
| Acta medica Okayama 2025 Dec; 79(6): 451-455 |
Emicizumab, a bispecific monoclonal antibody, benefits patients with severe hemophilia A. It alters laboratory assessments of coagulation activity, requiring anti-idiotype monoclonal antibodies for accurate...
En savoir plus
|
Free Full-text
|
|
 |
|
|
Informer un confrère
|
Modifier votre profil
|
Supprimer mes données
|
Sources et critères
|
|
|
